Pharmaceutical Quality Assurance of Diazepam Injection at the National Health Laboratory of Mali
Main Article Content
Abstract
Objectives: In a world marked by the increase in chemoresistance leading to the adoption of therapeutic combinations, the advent of generic multi-source drugs, the spread of counterfeiting and substandard drugs, often without active ingredients or falsified active ingredients, a Greater vigilance by pharmaceutical regulatory authorities is needed. Drug Post-Marketing Surveillance (PMS) therefore plays an important role in detecting poor quality products on the market.
Methods: The survey covered certain regions and certain points of sale. It aimed to assess the quality of Diazepam injection available on the market. The selection of drugs and geographic areas was made using risk-based sampling using the Drug Risk Assessment Tool (MedRS) developed by USP / PQM +.
Results: A total of 44 samples were analyzed according to a risk-based protocol, of which 32 were compliant with a rate of 91% against 12 non-compliant or 9% (P≤0,05). Non-compliant drugs were mainly from the public sector. We also found that all samples were unregistered.
Conclusion: The results clearly raise the issue of registration of drugs before their market authorization and the importance of continuous quality control and post-marketing drug analysis to ensure health and guarantee access to quality medicines for the health and well-being of populations.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. J. P. Hullihan, S. Spector, T. Taniguchi, et J. K. Wang, « The binding of [3H]-diazepam to guinea-pig ileal longitudinal muscle and the in vitro inhibition of contraction by benzodiazepines », Br J Pharmacol, vol. 78, no 2, p. 321‑327, févr. 1983, doi: 10.1111/j.1476-5381.1983.tb09397.x.
II. ALCOHOL WITHDRAWAL TREATMENT IN INTOXICATED VS NON-INTOXICATED PATIENTS: A CONTROLLED OPEN-LABEL STUDY WITH TIAPRIDE/CARBAMAZEPINE, CLOMETHIAZOLE AND DIAZEPAM | Alcohol and Alcoholism | Oxford Academic ». https://academic.oup.com/alcalc/article/38/2/168/195885 (consulté le 9 novembre 2022).
III. M. M. Savi, D. I. Obradovi, N. D. Ugrešić, et D. R. Bokonji, « The Influence of Diazepam on Atropine Reversal of Behavioural Impairment in Dichlorvos-Treated Rats », Pharmacology & Toxicology, vol. 93, no 5, p. 211‑218, 2003, doi: 10.1046/j.1600-0773.2003.pto930503.x.
IV. Diazepam Antidote:2004 ».
https://inchem.org/documents/antidote/antidote/diazepam.htm (consulté le 9 novembre 2022).
V. M. Uchibayashi, « [Leo Sternbach, an inventor of benzodiazepines] », Yakugaku Zasshi, vol. 127, no 1, p. 217‑224, janv. 2007,
doi: 10.1248/yakushi.127.217.
VI. Benzodiazepines Revisited | British Journal of Medical Practitioners ».
https://www.bjmp.org/content/benzodiazepines-revisited (consulté le 9 novembre 2022).
VII. C. Ferreyra et C. Ortiz, « Analysis of multicomponent formulations containing phenylpropanolamine hydrochloride, caffeine and diazepam by using LC », J Pharm Biomed Anal, vol. 25, no 3‑4, p. 493‑499, juin 2001, doi: 10.1016/s0731-7085(00)00599-9.
VIII. A. A. Mutair, P. A. Koya, et N. A. S. Al-Areqi, « Spectrophotometric Determination of Diazepam in Pharmaceutical Forms by Ion-Pairing with Ferrithiocyanide Complex », Science Journal of Analytical Chemistry, vol. 4, no 4, Art. no 4, juill. 2016, doi: 10.11648/j.sjac.20160404.12.
IX. Analytical methods for determination of benzodiazepines. A short review ».
https://www.researchgate.net/publication/261367085_Analytical_methods_for_determination_of_benzodiazepines_A_short_review (consulté le 9 novembre 2022).
X. Dans les pays en développement, 1 médicament sur 10 est de qualité inférieure ou falsifié ». https://www.who.int/fr/news/item/28-11-2017-1-in-10-medical-products-in-developing-countries-is-substandard-or-falsified (consulté le 9 novembre 2022).
XI. G. J. Buckley, L. O. Gostin, F. Committee on Understanding the Global Public Health Implications of Substandard, B. on G. Health, et I. of Medicine, Causes of Falsified and Substandard Drugs. National Academies Press (US), 2013. Consulté le: 9 novembre 2022. [En ligne]. Disponible sur:
https://www.ncbi.nlm.nih.gov/books/NBK202531/
XII. Produits médicaux de qualité inférieure ou falsifiés ». https://www.who.int/fr/news-room/fact-sheets/detail/substandard-and-falsified-medical-products (consulté le 9 novembre 2022).
XIII. USP-NF 〈698〉 Deliverable Volume ».
https://online.uspnf.com/uspnf/document/1_GUID-5D94F013-C3EF-4A3A-8254-4A22D052C8A9_2_en-US?source=TOC (consulté le 14 novembre 2022).
XIV. GPHF | GPHF-MinilabTM: Main manual now updated and extended ».
https://www.gphf.org/en/minilab/manuals.htm (consulté le 9 novembre 2022).
XV. L. Hoellein, E. Kaale, Y. H. Mwalwisi, M. H. Schulze, C. Vetye-Maler, et U. Holzgrabe, « Emerging Antimicrobial Drug Resistance in Africa and Latin America: Search for Reasons », Risk Manag Healthc Policy, vol. 15, p. 827‑843, avr. 2022, doi: 10.2147/RMHP.S205077.
XVI. Diazepam Injection - British Pharmacopoeia ». https://www.pharmacopoeia.com/bp-2022/formulated-specific/diazepam-injection.html?date=2022-07-01&text=Diazepam (consulté le 9 novembre 2022).
XVII. USP-NF Diazepam Injection ».
https://online.uspnf.com/uspnf/document/1_GUID-00C17D36-8C6D-498A-8059-5AA02450E633_3_en-US?source=TOC (consulté le 9 novembre 2022).
XVIII. [18] A Sidibé O. Quality control of medicines antimalarials in seven (07) administratives regions of Mali and Bamako district: operationalization of minilab kits. Published online 2012. Accessed April 2, 2021.
XIX. O. Dembélé, S. Coulibaly, J. Dakouo, et B. Koumaré, « PRE- AND POST-MARKETING CONTROL OF DRUG QUALITY AT THE NATIONAL HEALTH LABORATORY, BAMAKO-MALI », Universal Journal of Pharmaceutical Research, janv. 2022,
doi: 10.22270/ujpr.v6i6.696.